Phaseline

Targets › RAF

RAF (RAF proto-oncogene serine/threonine-protein kinase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology.

Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential…. (UniProt, P04049)

Open in Phaseline: the race on RAF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
West China HospitalDonafenib
Multi-targeted tyrosine kinase inhibitor targeting RAF, VEGFR, and FLT3
RAF, VEGFR, FLT3Phase 2Locally Advanced Thyroid Gland Carcinoma–

Conditions

Locally Advanced Thyroid Gland Carcinoma (1)

Modalities

small molecule (1)

Companies

West China Hospital (1)

Related targets

VEGFR (1) FLT3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.